Trial Profile
A prospective phase II study of cetuximab (Erbitux) in combination with XELOX [XELoda (capecitabine) and OXaliplatin] in patients with advanced gastric cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2020
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 16 Feb 2010 Actual patient number (44) added as reported by ClinicalTrials.gov.
- 14 Dec 2006 New trial record.